Abbott Laboratories Receives FDA Approval to Include Interactive Features in CardioMEMS Heart Monitor

MT newswire2026/10/05 13:58

09:58 AM EDT, 10/05/2026 (MT Newswires) -- Abbott Laboratories (ABT) said Monday that it has received US Food and Drug Administration approval for technology that provides updates directly to patients through its CardioMEMS HF System. The company said the technology allows doctors to share daily heart pressure readings directly with patients between office visits. It said the technology also provides the ability to send medication adjustment instructions to patients' smartphones and measures pressure through an implanted sensor in the pulmonary artery. Abbott said it plans to make CardioGuide HF App and Dynamic Treatment Plan available later in the year. Price: 97.69, Change: +0.19, Percent Change: +0.19

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Wihlborgs to host Q3 webcast and conference call after interim report release

Bitget•2026/10/13 05:30

Bank of America warns that gold is unlikely to hold above $4,000 in the short term, and a real bottom requires waiting for three signals.

金十数据•2026/10/13 04:57

GBP/USD Price Forecast: Defends 1.3200 as bears await two-week-old range breakdown

FXStreet•2026/10/13 04:45

Wall Street Expects 29.6% Q3 Earnings Growth: Can AI Stocks Deliver?

BeInCrypto•2026/10/13 03:42